HER2阳性晚期乳腺癌靶向治疗药物分类及临床研究进展  

Progress on Classification and Clinical Research of Targeted Drugs for HER2-Positive Advanced Breast Cancer

作　　者：姜明霞 李俏 徐兵河 JIANG Mingxia;LI Qiao;XU Binghe(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院,北京100021

出　　处：《中国肿瘤》2024年第7期583-595,共13页China Cancer

基　　金：中国医学科学院医学与健康科技创新工程(2021-I2M-1-014);中国医学科学院医学与健康科技创新工程(2022-I2M-JB-009)。

摘　　要：人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)是乳腺癌已知的重要分子靶点。HER2作为原癌基因之一,通常与侵袭性、复发转移及较差预后相关。抗HER2药物曲妥珠单抗的临床应用,大大改善了HER2阳性乳腺癌的诊疗模式和预后,并成为乳腺癌抗HER2靶向治疗的里程碑。HER2阳性晚期乳腺癌患者除存在禁忌情况外,应尽早进行抗HER2治疗。全文就HER2阳性晚期乳腺癌靶向治疗的药物分类及其研究进展作一综述,以期为晚期乳腺癌靶向治疗研究提供新思路。Human epidermal growth factor receptor 2(HER2)is an essential molecular target point known for breast cancer.As one of the proto-oncogenes,HER2 is usually associated with invasiveness,recurrence and metastasis,and poor prognosis.The clinical application of trastuzumab(anti-HER2 strategy)has dramatically improved the diagnosis,treatment mode,and prognosis of HER2-positive breast cancer and has become a milestone in anti-HER2-targeted breast cancer therapy.HER2-positive advanced breast cancer(ABC)patients should receive anti-HER2 treatment as soon as possible,except for contraindications.This paper reviews the drug classification and progress of targeted therapy for HER2-positive ABC to provide new insights for the study of targeted therapy for ABC.

关 键 词：晚期乳腺癌 人表皮生长因子受体2 靶向治疗 单克隆抗体 抗体偶联药物 

分 类 号：R737.7[医药卫生—肿瘤]